CHARLES RIVER LABORATORIES (CRL) Forecast, Price Target & Analyst Ratings

NYSE:CRL • US1598641074

Current stock price

163.84 USD
-2.95 (-1.77%)
At close:
163.84 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHARLES RIVER LABORATORIES (CRL).

Forecast Snapshot

Consensus Price Target

Price Target
$206.55
+ 26.07% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$1.96
Revenue Estimate
987.53M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
78.26%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$206.55
Upside
+ 26.07%
From current price of $163.84 to mean target of $206.55, Based on 23 analyst forecasts
Low
$158.01
Median
$204.00
High
$278.25

Price Target Revisions

1 Month
0.13%
3 Months
-1.01%

Price Target Summary

23 Wall Street analysts provided a forecast for the next 12 months for CRL. The average price target is 206.55 USD. This implies a price increase of 26.07% is expected in the next year compared to the current price of 163.84.
The average price target has been revised downward by 1.01% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CRL Current Analyst RatingCRL Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

CRL Historical Analyst RatingsCRL Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
78.26%
CRL was analyzed by 23 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CRL.
In the previous month the buy percentage consensus was at a similar level.
CRL was analyzed by 23 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-14BarclaysMaintains Overweight -> Overweight
2026-04-13JP MorganMaintains Neutral -> Neutral
2026-02-25UBSMaintains Neutral -> Neutral
2026-02-20TD CowenMaintains Buy -> Buy
2026-02-20MizuhoMaintains Neutral -> Neutral
2026-02-19BarclaysMaintains Overweight -> Overweight
2026-02-19Evercore ISI GroupMaintains Outperform -> Outperform
2026-01-16CitigroupMaintains Buy -> Buy
2026-01-13Evercore ISI GroupMaintains Outperform -> Outperform
2025-12-18MizuhoMaintains Neutral -> Neutral
2025-12-15BarclaysMaintains Overweight -> Overweight
2025-12-15JP MorganMaintains Neutral -> Neutral
2025-11-11Morgan StanleyMaintains Equal-Weight -> Equal-Weight
2025-11-10TD CowenMaintains Buy -> Buy
2025-11-06BarclaysMaintains Overweight -> Overweight
2025-11-06JP MorganMaintains Neutral -> Neutral
2025-11-06BairdUpgrade Neutral -> Outperform
2025-10-17MizuhoMaintains Neutral -> Neutral
2025-10-06William BlairUpgrade Market Perform -> Outperform
2025-10-03Evercore ISI GroupMaintains Outperform -> Outperform
2025-10-02BarclaysUpgrade Equal-Weight -> Overweight
2025-09-09JefferiesUpgrade Hold -> Buy
2025-08-08Evercore ISI GroupMaintains Outperform -> Outperform
2025-08-07BarclaysMaintains Equal-Weight -> Equal-Weight
2025-08-07JP MorganMaintains Neutral -> Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$1.96
Revenue Estimate
987.53M
Revenue Q2Q
0.34%
EPS Q2Q
-16.11%
Number of Analysts
15

Next Earnings Revisions

Revenue (1 Month)
-0.27%
Revenue (3 Months)
-1.84%
EPS (1 Month)
0.69%
EPS (3 Months)
-23.99%

Next Earnings Summary

CRL is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 1.96 USD and the consensus revenue estimate is 987.53M USD.
The next earnings revenue estimate has been revised downward by 1.84% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CRL revenue by date.CRL revenue by date.
4.129B
3.86%		4.05B
-1.92%		4.015B
-0.85%		3.974B
-1.03%		4.095B
3.04%		4.274B
4.37%		4.499B
5.26%		4.617B
2.62%		5.094B
10.33%		5.242B
2.91%		5.372B
2.48%
EBITDA
YoY % growth
CRL ebitda by date.CRL ebitda by date.
973.446M
1.02%		912.573M
-6.25%		905.462M
-0.78%		986.28M
8.93%		1.057B
7.17%		1.092B
3.31%		1.247B
14.19%		1.349B
8.18%		1.452B
7.64%		1.419B
-2.27%		1.374B
-3.17%
EBIT
YoY % growth
CRL ebit by date.CRL ebit by date.
659.322M
-0.06%		550.832M
-16.45%		502.15M
-8.84%		790.2M
57.36%		869.96M
10.09%		871M
0.12%		1.01B
15.96%		1.07B
5.94%		N/AN/AN/A
Operating Margin
CRL operating margin by date.CRL operating margin by date.
15.97%13.60%12.51%19.88%21.24%20.38%22.45%23.18%N/AN/AN/A
EPS
YoY % growth
CRL eps by date.CRL eps by date.
10.65
-4.31%		10.32
-3.10%		10.28
-0.39%		11.14
8.35%		12.28
10.23%		13.44
9.48%		16.31
21.31%		17.77
8.95%		19.84
11.65%		19.40
-2.19%		18.93
-2.45%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		1.96
-16.11%		2.76
-11.46%		3.12
28.22%		3.30
37.88%		2.57
30.78%		3.00
8.71%		3.27
4.87%		3.40
3.13%		3.02
17.50%		3.54
17.78%		3.47
6.10%		3.53
3.80%
Revenue
Q2Q % growth		987.53M
0.34%		1.011B
-2.05%		985.78M
-1.90%		990.11M
-0.41%		982.64M
-0.50%		1.017B
0.59%		1.024B
3.88%		1.031B
4.13%		1.061B
7.97%		1.11B
9.14%		1.102B
7.62%		1.105B
7.18%
EBITDA
Q2Q % growth		200.09M
-8.58%		255.05M
-31.48%		272.8M
-42.70%		282.5M
-46.04%		240.94M
20.42%		268.43M
5.25%		282.22M
3.45%		288.45M
2.11%		273.1M
13.35%		302.8M
12.80%		301.79M
6.93%		303.56M
5.24%
EBIT
Q2Q % growth		153.42M
55.73%		209.03M
57.96%		223.67M
48.05%		233.39M
94.14%		193.39M
26.05%		216.26M
3.46%		229.01M
2.39%		234.65M
0.54%		198.16M
2.47%		239.37M
10.69%		228.06M
-0.41%		219.07M
-6.64%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
9.35%
EPS Next 5 Year
11.56%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
1.84%
Revenue Next 5 Year
2.67%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
11.49%
EBIT Next 5 Year
11.35%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CHARLES RIVER LABORATORIES / CRL Forecast FAQ

What is the price target for CRL stock?

23 analysts have analysed CRL and the average price target is 206.55 USD. This implies a price increase of 26.07% is expected in the next year compared to the current price of 163.84.

When does CHARLES RIVER LABORATORIES (CRL) report earnings?

CHARLES RIVER LABORATORIES (CRL) will report earnings on 2026-05-07, before the market open.

Can you provide the consensus estimates for CHARLES RIVER LABORATORIES next earnings?

The consensus EPS estimate for the next earnings of CHARLES RIVER LABORATORIES (CRL) is 1.96 USD and the consensus revenue estimate is 987.53M USD.

Can you provide the analyst count for CHARLES RIVER LABORATORIES stock?

The number of analysts covering CHARLES RIVER LABORATORIES (CRL) is 23.